NFKB1 and Alzheimer disease: It has been widely studied and proven to be an anti-aging and anti-inflammatory agent, acting via SIRT1, NF-κB, and MAPK signaling (Shal et al., 2018), and is a particularly promising agent for the treatment of AD (Sawda et al., 2017).